This is an old revision of this page, as edited by LFaraone (talk | contribs) at 04:50, 22 May 2013 (Reverted good faith edit(s) by Dclutz using STiki). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 04:50, 22 May 2013 by LFaraone (talk | contribs) (Reverted good faith edit(s) by Dclutz using STiki)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | |
| Company type | Public |
|---|---|
| Traded as | Nasdaq: ANTH |
| Industry | Pharmaceuticals |
| Founded | 2004 |
| Headquarters | Hayward, California, U.S. |
| Key people | Paul F. Truex (President and CEO) |
| Website | Anthera.com |
Anthera Pharmaceuticals, Inc. is a pharmaceutical company that specializes in developing treatments for serious cardiovascular and autoimmune diseases. It is headquartered in Hayward, California.
Product Candidates
Anthera has one drug in Phase III of clinical development, and two in Phase II.
- Varespladib methyl, an investigational anti-inflammatory agent for the treatment of acute coronary syndrome. The drug was closed to study in March 2012, with patients taken off of it, with the company citing lack of effectiveness in the trials.
- Blisibimod, an investigational anti-BAFF molecule for the treatment of systemic lupus erythematosus.
- Varespladib sodium, an investigational anti-inflammatory agent for the treatment of acute chest syndrome.
References
- ^ "Form 10-K, Anthera Pharmaceuticals, Inc". U.S. Securities and Exchange Commission. March 7, 2011.
- "Product Cantidates: Overview". Anthera Pharmaceuticals, Inc. Retrieved August 4, 2011.
- Flinn, Ryan (March 12, 2012). "Anthera Shares Plunge on Stopping Heart Trial for Lack of Effectiveness". Bloomberg.
